In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

With autoimmune pancreatitis linked to a higher cancer risk, doctors must use comprehensive imaging to avoid unnecessary ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung ...

Inebilizumab for treating generalised myasthenia gravis [TSID12110] Technology appraisal guidance Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 ...

Amgen acquired CD19-directed antibody Uplizna (inebilizumab) as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, and already has approval for the drug in AQP4 antibody-positive ...

In NMOSD, Soliris is also facing competition from Horizon Therapeutics' CD19-directed cytolytic antibody Uplizna (inebilizumab) and Roche's IL-6 inhibitor Enspryng (satralizumab). In the first ...

Alector has announced the completion of enrollment for its Phase II clinical trial, PROGRESS-AD, evaluating the safety and ...

Dupilumab is now approved for CSU patients aged 12+ not controlled by H1 antihistamines, targeting IL-4 and IL-13 pathways. Phase 3 trials showed significant reductions in itch and urticaria ...

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 ...

The table below is a review of notable updates that occurred in March 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.